Skip to main content

Advertisement

SpringerLink
Log in

Evaluation and management of dyslipidemia in patients with HIV infection

  • Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

OBJECTIVE: Persons with HIV infection develop metabolic abnormalities related to their antiretroviral therapy and HIV infection itself. The objective of this study was to summarize the emerging evidence for the incidence, etiology, health risks, and treatment of dyslipidemias in HIV disease.

DESIGN: Systematic review of original research with quantitative synthesis.

MAIN RESULTS: Dyslipidemia is common in persons with HIV infection on highly active antiretroviral therapy (HAART), but methodologic differences between studies preclude precise estimates of prevalence and incidence. The typical pattern includes elevated total cholesterol, low-density lipoprotein cholesterol, and triglycerides, which may be markedly elevated. The dyslipidemia may be associated with lipodys-trophy, insulin resistance, and, rarely, frank diabetes mellitus. Exposure to protease inhibitors (PIs) is associated with this entire range of metabolic abnormalities. PI-naïve patients on nucleoside reverse transcriptase inhibitors (NRTIs) may develop lipodystrophy, insulin resistance, hypercholesterolemia, and possibly modest elevations in triglycerides but not severe hypertriglyceridemia, which appears to be linked to PIs alone. Most studies have not found an association between CD4 lymphocyte count or HIV viral load and lipid abnormalities. The pathogenesis is incompletely understood and appears to be multifactorial. There are insufficient data to definitively support an increased coronary heart disease risk in patients with HIV-related dyslipidemia. However, some of the same metabolic abnormalities remain firmly established risk factors in other populations. Patients on HAART with severe hypertriglyceridemia may develop pancreatitis or other manifestations of the chylomicronemia syndrome. Some of the metabolic derangements (particularly hypertriglyceridemia) may improve upon replacing a PI with a non-nucleoside reverse transcriptase inhibitor. The limited experience suggests that fibrates, pravastatin, and atorvastatin can safely treat lipid abnormalities in HIV-infected patients.

CONCLUSIONS: Patients with HIV infection on HAART should be screened for lipid disorders, given their incidence, potential for morbidity, and possible long-term cardiovascular risk. Treatment decisions are complex and must include assessments of cardiac risk, HIV infection status, reversibility of the dyslipidemia, and the effectiveness and toxicities of lipid-lowering medications. The multiple potential drug interactions with antiretroviral or other HIV-related medications should be considered in lipid-lowering drug selection and monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. [see comments]. N Engl J Med. 1997;337:725–33.

    Article  PubMed  CAS  Google Scholar 

  2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–9.

    Article  PubMed  CAS  Google Scholar 

  3. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. [see comments]. N Engl J Med. 1998;338:853–60.

    Article  PubMed  Google Scholar 

  4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. [see comments]. Lancet. 1999;353:2093–9.

    Article  PubMed  CAS  Google Scholar 

  5. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050–6.

    Article  PubMed  CAS  Google Scholar 

  6. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231–9.

    Article  PubMed  CAS  Google Scholar 

  7. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994;24:416–20.

    Article  PubMed  CAS  Google Scholar 

  8. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045–52.

    Article  PubMed  CAS  Google Scholar 

  9. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:1149–56.

    PubMed  CAS  Google Scholar 

  10. Garg A. Lipodystrophies. Am J Med. 2000;108:143–52.

    Article  PubMed  CAS  Google Scholar 

  11. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother. 1999;33:859–63.

    Article  PubMed  CAS  Google Scholar 

  12. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11:938–9.

    Article  PubMed  CAS  Google Scholar 

  13. Pujol RM, Domingo P, Xavier Matias G, et al. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases. J Am Acad Dermatol. 2000;42:193–8.

    Article  PubMed  CAS  Google Scholar 

  14. Panse I, Vasseur E, Raffin-Sanson ML, Staroz F, Rouveix E, Saiag P. Lipodystrophy associated with protease inhibitors. Br J Dermatol. 2000;142:496–500.

    Article  PubMed  CAS  Google Scholar 

  15. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–70.

    Article  PubMed  CAS  Google Scholar 

  16. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–8.

    Article  PubMed  CAS  Google Scholar 

  17. Koppel K, Bratt G, Eriksson M, Sandstrom E. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS. 2000;11:451–5.

    Article  PubMed  CAS  Google Scholar 

  18. Garcia-Benayas T, Blanco F, de la Cruz JJ, et al. Role of nonnucleosides in the development of HAART-related lipid disturbances. J Acquir Immune Defic Syndr. 2001;28:496–8.

    PubMed  CAS  Google Scholar 

  19. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181–8.

    Article  PubMed  CAS  Google Scholar 

  20. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700–5.

    PubMed  CAS  Google Scholar 

  21. Roge BT, Katzenstein TL, Gerstoft J. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scand J Infect Dis. 2001;33:306–11.

    Article  PubMed  CAS  Google Scholar 

  22. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;29:441–3.

    PubMed  CAS  Google Scholar 

  23. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS. 2001;12:463–8.

    Article  PubMed  CAS  Google Scholar 

  24. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P, Valentin VD. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d’Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defic Syndr. 2000;23:261–5.

    PubMed  CAS  Google Scholar 

  25. Boufassa F, Dulioust A, Lascaux AS, et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials. 2001;2:339–45.

    Article  PubMed  CAS  Google Scholar 

  26. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659–67.

    Article  PubMed  CAS  Google Scholar 

  27. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999;13:735–7.

    Article  PubMed  CAS  Google Scholar 

  28. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. “Buffalo hump” in men with HIV-1 infection. [see comments]. Lancet. 1998;351:867–70.

    Article  PubMed  CAS  Google Scholar 

  29. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27:443–9.

    PubMed  CAS  Google Scholar 

  30. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21–31.

    PubMed  CAS  Google Scholar 

  31. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237–44.

    PubMed  CAS  Google Scholar 

  32. van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847–55.

    Article  PubMed  Google Scholar 

  33. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389–98.

    Article  PubMed  CAS  Google Scholar 

  34. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS. 2001;15:1993–2000.

    Article  PubMed  CAS  Google Scholar 

  35. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130–9.

    Article  PubMed  CAS  Google Scholar 

  36. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–71.

    Article  PubMed  CAS  Google Scholar 

  37. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 1999;21:107–13.

    PubMed  CAS  Google Scholar 

  38. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection. 1999;27:77–81.

    Article  PubMed  CAS  Google Scholar 

  39. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–8.

    Article  PubMed  CAS  Google Scholar 

  40. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167–73.

    Article  PubMed  CAS  Google Scholar 

  41. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881–3.

    Article  PubMed  CAS  Google Scholar 

  42. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112–5.

    Article  PubMed  CAS  Google Scholar 

  43. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493–505.

    Article  PubMed  CAS  Google Scholar 

  44. Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet. 1999;354:76.

    Article  PubMed  CAS  Google Scholar 

  45. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000;20:2625–9.

    PubMed  CAS  Google Scholar 

  46. Grunfeld C, Doerrler W, Pang M, Jensen P, Weisgraber KH, Feingold KR. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1997;82:3734–40.

    Article  PubMed  CAS  Google Scholar 

  47. Paganelli R, Mezzaroma I, Mazzone AM, Pinter E, Aiuti F. Leptin levels in HIV-positive patients treated with HAART. AIDS. 1999;13:2479.

    Article  PubMed  CAS  Google Scholar 

  48. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol. 2001;12:313–9.

    Article  PubMed  CAS  Google Scholar 

  49. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr. 2000;25:S4–11.

    Article  PubMed  CAS  Google Scholar 

  50. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327–31.

    Article  PubMed  CAS  Google Scholar 

  51. Allan DA, Behrman AJ. Lipid abnormalities in a healthcare worker receiving HIV prophylaxis. Int J STD AIDS. 2001;12:532–4.

    Article  PubMed  CAS  Google Scholar 

  52. Zaera MG, Miro O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS. 2001;15:1643–51.

    Article  PubMed  CAS  Google Scholar 

  53. Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS. 2001;15:413–5.

    Article  PubMed  CAS  Google Scholar 

  54. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 2001;15:2397–406.

    Article  PubMed  CAS  Google Scholar 

  55. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925–31.

    Article  PubMed  CAS  Google Scholar 

  56. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter; comment]. Lancet. 1998;351:1958.

    Article  PubMed  CAS  Google Scholar 

  57. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. [letter]. [see comments]. Lancet. 1998;351:1328.

    Article  PubMed  CAS  Google Scholar 

  58. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors [letter; comment]. Lancet. 1998;351:1959.

    Article  PubMed  CAS  Google Scholar 

  59. Eriksson U, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS. 1998;12:2079–80.

    Article  PubMed  CAS  Google Scholar 

  60. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med. 1999;131:548.

    PubMed  CAS  Google Scholar 

  61. Muise A, Arbess G. The risk of myocardial infarction in HIV-infected patients receiving HAART: a case report. Int J STD AIDS. 2001;12:612–3.

    Article  PubMed  CAS  Google Scholar 

  62. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS. 2001;15:329–34.

    Article  PubMed  CAS  Google Scholar 

  63. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257–62.

    PubMed  CAS  Google Scholar 

  64. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535–9.

    Article  PubMed  CAS  Google Scholar 

  65. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899–906.

    PubMed  CAS  Google Scholar 

  66. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. [see comments]. N Engl J Med. 1995;332:488–93.

    Article  PubMed  CAS  Google Scholar 

  67. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res. 2000;5:329–33.

    PubMed  CAS  Google Scholar 

  68. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–9.

    Article  PubMed  CAS  Google Scholar 

  69. Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk. [see comments]. Arch Intern Med. 2000;160:1937–44.

    Article  PubMed  CAS  Google Scholar 

  70. Schmitz M, Michl GM, Walli R, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2001;26:225–35.

    Article  PubMed  CAS  Google Scholar 

  71. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B-25B.

    Article  PubMed  CAS  Google Scholar 

  72. Sprecher DL, Pearce GL. How deadly is the “deadly quartet”? A post-CABG evaluation. J Am Coll Cardiol. 2000;36:1159–65.

    Article  PubMed  CAS  Google Scholar 

  73. Brunzell JD, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am. 1982;66:455–68.

    PubMed  CAS  Google Scholar 

  74. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis. 1999;28:161–2.

    Article  PubMed  CAS  Google Scholar 

  75. Eng KT, Liu ES, Silverman MS, Berger AR. Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors. Arch Ophthalmol. 2000;118:425–6.

    PubMed  CAS  Google Scholar 

  76. Press N, Montessori V, Bai TR, Montaner J. Respiratory failure associated with the lipodystrophy syndrome in an HIV-positive patient with compromised lung function. Can Respir J. 2001;8:279–82.

    PubMed  CAS  Google Scholar 

  77. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS. 1999;13:2188–9.

    Article  PubMed  CAS  Google Scholar 

  78. Moyle G, Baldwin C. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Read. 2000;10:479–85.

    PubMed  CAS  Google Scholar 

  79. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. [letter]. [see comments]. Lancet. 1998;352:1031–2.

    Article  PubMed  CAS  Google Scholar 

  80. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001;15:1503–8.

    Article  PubMed  CAS  Google Scholar 

  81. Thomas JC, Lopes-Virella MF, Del Bene VE, et al. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000;20:727–34.

    Article  PubMed  CAS  Google Scholar 

  82. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472–7.

    Article  PubMed  CAS  Google Scholar 

  83. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999;13:2099–103.

    Article  PubMed  CAS  Google Scholar 

  84. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. [see comments]. Ann Intern Med. 2000;133:263–74.

    PubMed  CAS  Google Scholar 

  85. Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet. 1999;353:1244.

    Article  PubMed  CAS  Google Scholar 

  86. Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis. 2000;31:1216–24.

    Article  PubMed  CAS  Google Scholar 

  87. Perez A, Wagner AM, Carreras G, et al. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. Arch Intern Med. 2000;160:2756–62.

    Article  PubMed  CAS  Google Scholar 

  88. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.

    PubMed  CAS  Google Scholar 

  89. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). [see comments]. JAMA. 2001;285:2486–97.

    Google Scholar 

  90. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568–77.

    Article  PubMed  CAS  Google Scholar 

  91. Fruchart JC, Brewer HB Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol. 1998;81:912–7.

    Article  PubMed  CAS  Google Scholar 

  92. Goldberg AC. Fenofibrate for the treatment of type IV and V hyperlipoproteinemia: a double-blind, placebo-controlled multi-center US study. Clin Ther. 1989;11:69–83.

    PubMed  CAS  Google Scholar 

  93. Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J. 2000;140:232–40.

    Article  PubMed  CAS  Google Scholar 

  94. Manttari M, Koskinen P, Manninen V, Huttunen JK, Frick MH, Nikkila EA. Effect of gemfibrozil on the concentration and composition of serum lipoproteins. A controlled study with special reference to initial triglyceride levels. Atherosclerosis. 1990;81:11–7.

    Article  PubMed  CAS  Google Scholar 

  95. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb. 1993;13:702–11.

    PubMed  CAS  Google Scholar 

  96. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med. 2000;160:1177–84.

    Article  PubMed  CAS  Google Scholar 

  97. Schwenk TL, Fisher M. Hepatitis caused by low-dose sustained-release niacin. J Am Board Fam Pract. 1994;7:242–4.

    PubMed  CAS  Google Scholar 

  98. Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc. 1991;66:23–8.

    PubMed  CAS  Google Scholar 

  99. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723–6.

    Article  PubMed  CAS  Google Scholar 

  100. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ. 2000;321:983–6.

    Article  PubMed  CAS  Google Scholar 

  101. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-9B.

    Article  PubMed  CAS  Google Scholar 

  102. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91:25S-30S.

    Article  PubMed  CAS  Google Scholar 

  103. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J.

    Article  PubMed  CAS  Google Scholar 

  104. Farnier M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol. 2000;85:53–7.

    Article  PubMed  CAS  Google Scholar 

  105. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998;81:60B-5B.

    Article  PubMed  CAS  Google Scholar 

  106. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J. 1995;16:5–13.

    PubMed  CAS  Google Scholar 

  107. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993;94:13–20.

    Article  PubMed  CAS  Google Scholar 

  108. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71–5.

    Article  PubMed  CAS  Google Scholar 

  109. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511.

    Article  PubMed  CAS  Google Scholar 

  110. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med. 2000;160:2273–80.

    Article  PubMed  CAS  Google Scholar 

  111. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984–96.

    Article  PubMed  CAS  Google Scholar 

  112. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44:190–4.

    Article  PubMed  CAS  Google Scholar 

  113. Mastroianni CM, d’Ettorre G, Forcina G, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS. 2001;15:820–1.

    Article  PubMed  CAS  Google Scholar 

  114. Murillas J, Martin T, Ramos A, Portero JL. Atorvastatin for protease inhibitor-related hyperlipidaemia. [letter]. AIDS. 1999;13:1424–5.

    Article  PubMed  CAS  Google Scholar 

  115. Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS. 2000;14:1660–2.

    Article  PubMed  CAS  Google Scholar 

  116. Anonymous. Choice of lipid lowering drugs. Med Lett Drugs Ther. 1998;40:117–22.

    Google Scholar 

  117. Churchill DR, Pym AS, Babiker AG, Back DJ, Weber JN. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. Br J Clin Pharmacol. 1998;46:518–9.

    PubMed  CAS  Google Scholar 

  118. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528–33.

    Article  PubMed  CAS  Google Scholar 

  119. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS. 2000;14:807–12.

    Article  PubMed  CAS  Google Scholar 

  120. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001;15:1811–22.

    Article  PubMed  CAS  Google Scholar 

  121. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27:229–36.

    PubMed  CAS  Google Scholar 

  122. Wensing AM, Reedijk M, Richter C, Boucher CA, Borleffs JC. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS. 2001;15:2191–3.

    Article  PubMed  CAS  Google Scholar 

  123. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res. 2001;6:413–21.

    PubMed  CAS  Google Scholar 

  124. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805–10.

    Article  PubMed  CAS  Google Scholar 

  125. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000;31:1266–73.

    Article  PubMed  CAS  Google Scholar 

  126. Duncombe C. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir. J Acquir Immune Defic Syndr. 2000;24:78–9.

    PubMed  CAS  Google Scholar 

  127. Doser N, Sudre P, Telenti A, et al. Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr. 2001;26:389–90.

    PubMed  CAS  Google Scholar 

  128. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. [letter]. AIDS. 1999;13:868–9.

    Article  PubMed  CAS  Google Scholar 

  129. de Luis DA, Bachiller P, Aller R. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor. Nutrition. 2001;17:414–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale Primary Care Residency Program, Waterbury Hospital, 64 Robbins St., 06721, Waterbury, CT

    Michael L. Green MD, MSc

Authors
  1. Michael L. Green MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael L. Green MD, MSc.

Additional information

Received from the Yale Primary Care Residency Program, Yale University School of Medicine, Department of Internal Medicine, New Haven, Conn; and Waterbury and St. Mary’s Hospitals, Waterbury, Conn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, M.L. Evaluation and management of dyslipidemia in patients with HIV infection. J GEN INTERN MED 17, 797–810 (2002). https://doi.org/10.1046/j.1525-1497.2002.20201.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.2002.20201.x

Key words

Search

Navigation